Drug intelligence / Profile preview

antithymocyte globulin + methylprednisolone

Development stage: Unknown
Lead developer: Sanofi
Modality: Small Molecules
Administration: Intravenous

Overview

A combination immunosuppressive therapy consisting of antithymocyte globulin (ATG) and methylprednisolone (MP). This regimen is primarily used for treating severe aplastic anemia and for preventing or treating graft-versus-host disease in transplant patients. The addition of methylprednisolone to ATG reduces side effects typically seen with ATG monotherapy while enhancing its beneficial immunosuppressive effects.

Other names: ATG + MP

Targets

GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on antithymocyte globulin + methylprednisolone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on antithymocyte globulin + methylprednisolone.

Explore the full profile